Verastem (VSTM) Gross Margin (2018 - 2026)

Verastem (VSTM) recorded quarterly Gross Margin of 85.15% in Q1 2026, little changed quarter-over-quarter from 85.1% in Q4 2025.

Verastem (VSTM) Gross Margin (2018 - 2026) Analysis & Trends

Verastem's Gross Margin history runs 5 years deep, the most recent figure standing at 85.15% for Q1 2026.

In Q1 2026, Gross Margin changed N/A year-over-year to 85.15%; the TTM figure through Mar 2026 stood at 85.13% (changed N/A YoY), while the FY2025 annual figure was 85.12%, changed N/A from the prior year.
Gross Margin was 85.15% for Q1 2026 at Verastem, roughly flat from 85.1% in the prior quarter.
In the past five years, Gross Margin ranged from a high of 85.15% in Q1 2026 to a low of 85.1% in Q4 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	79.04%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	86.85%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Verastem	407.42 Mn	225.74 Mn	15.90 Mn	85.15%

Historic Data

Download Data

Date	Value
Mar 31, 2026	85.15%
Dec 31, 2025	85.10%
Sep 30, 2025	85.14%
Jun 30, 2025	85.12%
Dec 31, 2020	97.63%
Sep 30, 2020	98.90%
Jun 30, 2020	90.90%
Mar 31, 2020	90.21%
Dec 31, 2019	90.82%
Sep 30, 2019	95.89%
Jun 30, 2019	87.98%
Mar 31, 2019	90.54%
Dec 31, 2018	90.41%
Sep 30, 2018	99.68%